Not only that, the administration of dactolisib was able to remodel the tumor microenvironment (TME) by enhancing the prevalence of anti-tumor immune cells, including T-CD4 cells and M1 macrophages, while simultaneously reducing the population of immune suppressive cells, including MDSCs and also M2 macrophages (Taghiloo et al., 2023; Li et al., 2020). Here, CD4 is linked to neoplasm.